John Sargent Sundy | Scholars@Duke

John Sargent Sundy
Adjunct Professor in the Department of Medicine

Research Theme

The focus of my research is on human-based translational studies and therapeutic trials of novel agents for inflammatory and immunologic diseases. My group has experience in mechanistic studies of environmental exposure in airway diseases; genetic analysis and gene expression studies using microarrays; airway challenge and assessment of response in the upper and lower airway and periphery; and therapeutic trials of experimental agents in Phases I-IV. Areas of focus include:

Asthma and Allergic Diseases

Research interests in asthma and allergic diseases focus upon human studies investigating the response to environmental endotoxin exposure. Using airway challenge with lipopolysaccharide and well characterized allergens, we investigate the genetic regulation of immunologic and inflammatory responses in the lung and in the periphery. This work is performed in collaboration with investigators with expertise in bench science and computational biology. In addition I participate in a number of multi-center research projects related to experimental therapeutics and genetic susceptibility to asthma and allergic diseases.

Rheumatologic Diseases

My primary research focus in rheumatologic diseases is on experimental therapeutics in chronic gout. Gout is the most common inflammatory arthritis in men, and the prevalence of disease is increasing in the population. We have led Phase I through III studies of pegloticase (PEGylated uricase) in subjects with treatment failure gout. We have initiated a new line of investigation that focuses upon IL-1 inhibition in the treatment of inflammation in acute and chronic gout.

Duke Clinical Research Institute - Multicenter Clinical Trials

I serve as the Director of Rheumatology and Allergy Research at the Duke Clinical Research Institute, a large academic research organization with expertise in the coordination of multi-center clinical trials and registries. Our objective is to develop a diverse portfolio of research registries and clinical trials in rheumatic and immunologic disease led by investigators at Duke. Currently our group is involved in programs in pediatric lupus, systemic onset JIA, gout, rheumatoid arthritis, and scleroderma.

Current Appointments & Affiliations

Adjunct Professor in the Department of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2014
Member in the Duke Clinical Research Institute, Duke Clinical Research Institute, Institutes and Centers 2010

Contact Information

Gilead Sciences, 333 Lakeside Dr, Foster City, CA 94404
Duke Box 3278, 3854 Clinic 3N, Duke Clinic, Durham, NC 27710
sundy001@mc.duke.edu (919) 684-2347

Background
Education, Training, & Certifications
- Fellow in Allergy and Immunology, Medicine, Duke University 1995 - 1998
- Fellow in Rheumatology, Medicine, Duke University 1993 - 1997
- Medical Resident, Medicine, Duke University 1991 - 1993
- M.D., Drexel University 1991
- Ph.D., Drexel University 1991
Duke Appointment History
- Associate Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2010 - 2014
- Associate Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2006 - 2010
- Assistant Professor of Medicine, Medicine, Rheumatology and Immunology, Medicine 2000 - 2006
- Associate in the Department of Medicine, Medicine, Rheumatology and Immunology, Medicine 1996 - 2000
Expertise
Global Scholarship
- Research
  - India (Country)
  - Singapore (Country)
Research
Selected Grants
- Interdisciplinary Training Program in Lung Disease awarded by National Institutes of Health 2009 - 2021
- Training Program in Inflammatory and Immunological Diseases awarded by National Institutes of Health 1980 - 2017
- Clinical Practice Data to Aid Narrow Therapeutic Index Drug Classification awarded by Food and Drug Administration 2013 - 2016
- Idiopathic Pulmonary Fibrosis Clinical Research Network NCE awarded by National Institutes of Health 2005 - 2014
- CARRA: Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology awarded by National Institutes of Health 2009 - 2013
- PEG-uricase as Therapy for Refractory Gout IND#11274 awarded by Food and Drug Administration 2004 - 2009
- Role of TLR4 in Environmental Asthma awarded by National Institutes of Health 2001 - 2007
- Management of Allergic Rhinitis in the Working-Aged Population awarded by Agency for Healthcare Research and Quality 2001 - 2003
- Mechanisms And Therapy Of Primary Immunodeficiency awarded by National Institutes of Health 1995 - 1999
- Research Training In Allergy And Clinical Immunology awarded by National Institutes of Health 1907 - 1999
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Combe, Bernard, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J Abraham Simon, Herbert S. B. Baraf, Uma Kumar, et al. “Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.” Ann Rheum Dis, January 27, 2021. https://doi.org/10.1136/annrheumdis-2020-219214.
    Full Text Link to Item
  - Takeuchi, Tsutomu, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, et al. “Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).” Mod Rheumatol, January 18, 2021, 1–16. https://doi.org/10.1080/14397595.2020.1859675.
    Full Text Link to Item
  - Westhovens, René, William F. C. Rigby, Désirée van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, et al. “Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.” Ann Rheum Dis, January 15, 2021. https://doi.org/10.1136/annrheumdis-2020-219213.
    Full Text Link to Item
  - Raghu, Ganesh, Brett Ley, Kevin K. Brown, Vincent Cottin, Kevin F. Gibson, Robert J. Kaner, David J. Lederer, et al. “Risk factors for disease progression in idiopathic pulmonary fibrosis.” Thorax 75, no. 1 (January 2020): 78–80. https://doi.org/10.1136/thoraxjnl-2019-213620.
    Full Text Link to Item
  - Chertow, Glenn M., Pablo E. Pergola, Fang Chen, Brian J. Kirby, John S. Sundy, Uptal D. Patel, and Uptal D. GS-US-223-1015 Investigators. “Effects of Selonsertib in Patients with Diabetic Kidney Disease.” J Am Soc Nephrol 30, no. 10 (October 2019): 1980–90. https://doi.org/10.1681/ASN.2018121231.
    Full Text Link to Item
  - Genovese, Mark C., Kenneth Kalunian, Jacques-Eric Gottenberg, Neelufar Mozaffarian, Beatrix Bartok, Franziska Matzkies, Jie Gao, et al. “Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.” Jama 322, no. 4 (July 23, 2019): 315–25. https://doi.org/10.1001/jama.2019.9055.
    Full Text Link to Item
  - Moore, Camille, Rachel Z. Blumhagen, Ivana V. Yang, Avram Walts, Julie Powers, Tarik Walker, Makenna Bishop, et al. “Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.” Am J Respir Crit Care Med 200, no. 2 (July 15, 2019): 199–208. https://doi.org/10.1164/rccm.201810-1891OC.
    Full Text Link to Item
  - Poe, Jonathan C., Wei Jia, Julie A. Di Paolo, Nancy J. Reyes, Ji Yun Kim, Hsuan Su, John S. Sundy, et al. “SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.” Jci Insight 3, no. 19 (October 4, 2018). https://doi.org/10.1172/jci.insight.122430.
    Full Text Link to Item
  - Humphries, Stephen M., Jeffrey J. Swigris, Kevin K. Brown, Matthew Strand, Qi Gong, John S. Sundy, Ganesh Raghu, et al. “Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.” Eur Respir J 52, no. 3 (September 2018). https://doi.org/10.1183/13993003.01384-2018.
    Full Text Link to Item
  - Sandborn, William J., Bal R. Bhandari, Charles Randall, Ziad H. Younes, Tomasz Romanczyk, Yan Xin, Emily Wendt, et al. “Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.” J Crohns Colitis 12, no. 9 (August 29, 2018): 1021–29. https://doi.org/10.1093/ecco-jcc/jjy049.
    Full Text Link to Item
  - Schreiber, Stefan, Corey A. Siegel, Keith A. Friedenberg, Ziad H. Younes, Ursula Seidler, Bal R. Bhandari, Ke Wang, et al. “A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease.” J Crohns Colitis 12, no. 9 (August 29, 2018): 1014–20. https://doi.org/10.1093/ecco-jcc/jjy070.
    Full Text Link to Item
  - Gossage, David L., Blanka Cieslarová, Sophe Ap, Hao Zheng, Yan Xin, Preeti Lal, Guang Chen, Victoria Smith, and John S. Sundy. “Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.” Clin Ther 40, no. 1 (January 2018): 156-165.e5. https://doi.org/10.1016/j.clinthera.2017.11.011.
    Full Text Link to Item
  - Wang, Jennifer M., Scott H. Robertson, Ziyi Wang, Mu He, Rohan S. Virgincar, Geoffry M. Schrank, Rose Marie Smigla, et al. “Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.” Thorax 73, no. 1 (January 2018): 21–28. https://doi.org/10.1136/thoraxjnl-2017-210070.
    Full Text Link to Item
  - Patel, Dhavalkumar D., Christian Antoni, Steven J. Freedman, Marc C. Levesque, and John S. Sundy. “Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases.” J Allergy Clin Immunol 140, no. 3 (September 2017): 685–87. https://doi.org/10.1016/j.jaci.2017.04.029.
    Full Text Link to Item
  - Suarez, Edward C., and John S. Sundy. “The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.” Health Psychol 36, no. 9 (September 2017): 852–62. https://doi.org/10.1037/hea0000517.
    Full Text Link to Item
  - Perez-Ruiz, Fernando, John S. Sundy, Jeffrey N. Miner, Matthew Cravets, Chris Storgard, and Chris RDEA594-203 Study Group. “Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.” Ann Rheum Dis 75, no. 6 (June 2016): 1074–80. https://doi.org/10.1136/annrheumdis-2015-207919.
    Full Text Link to Item
  - Andrade, Joao de, Marvin Schwarz, Harold R. Collard, Tedryl Gentry-Bumpass, Thomas Colby, David Lynch, Robert J. Kaner, and Robert J. IPFnet Investigators. “The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.” Chest 148, no. 4 (October 2015): 1034–42. https://doi.org/10.1378/chest.14-2889.
    Full Text Link to Item
  - Neogi, Tuhina, Tim L Th A. Jansen, Nicola Dalbeth, Jaap Fransen, H Ralph Schumacher, Dianne Berendsen, Melanie Brown, et al. “2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.” Arthritis Rheumatol 67, no. 10 (October 2015): 2557–68. https://doi.org/10.1002/art.39254.
    Full Text Link to Item
  - Neogi, Tuhina, Tim L Th A. Jansen, Nicola Dalbeth, Jaap Fransen, H Ralph Schumacher, Dianne Berendsen, Melanie Brown, et al. “2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.” Ann Rheum Dis 74, no. 10 (October 2015): 1789–98. https://doi.org/10.1136/annrheumdis-2015-208237.
    Full Text Link to Item
  - Smith, Lewis J., Ravi Kalhan, Robert A. Wise, Elizabeth A. Sugar, John J. Lima, Charles G. Irvin, Allen J. Dozor, Janet T. Holbrook, and Janet T. American Lung Association Asthma Clinical Research Centers. “Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial.” Jama 313, no. 20 (May 26, 2015): 2033–43. https://doi.org/10.1001/jama.2015.5024.
    Full Text Link to Item
  - Suarez, Edward C., John S. Sundy, and Alaattin Erkanli. “Depressogenic vulnerability and gender-specific patterns of neuro-immune dysregulation: What the ratio of cortisol to C-reactive protein can tell us about loss of normal regulatory control.” Brain Behav Immun 44 (February 2015): 137–47. https://doi.org/10.1016/j.bbi.2014.09.008.
    Full Text Link to Item
  - Baraf, Herbert S. B., Robert A. Yood, Faith D. Ottery, John S. Sundy, and Michael A. Becker. “Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.” J Clin Rheumatol 20, no. 8 (December 2014): 427–32. https://doi.org/10.1097/RHU.0000000000000200.
    Full Text Link to Item
  - Sundy, John S., H Ralph Schumacher, Alan Kivitz, Steven P. Weinstein, Richard Wu, Shirletta King-Davis, and Robert R. Evans. “Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.” J Rheumatol 41, no. 8 (August 2014): 1703–11. https://doi.org/10.3899/jrheum.131226.
    Full Text Link to Item
  - Hershfield, M. S., N. J. Ganson, S. J. Kelly, E. L. Scarlett, D. A. Jaggers, and J. S. Sundy. “Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.” Arthritis Research and Therapy 16, no. 2 (March 7, 2014). https://doi.org/10.1186/ar4500.
    Full Text
  - Hershfield, Michael S., Nancy J. Ganson, Susan J. Kelly, Edna L. Scarlett, Denise A. Jaggers, and John S. Sundy. “Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.” Arthritis Res Ther 16, no. 2 (March 7, 2014): R63. https://doi.org/10.1186/ar4500.
    Full Text Link to Item
  - Lipsky, Peter E., Leonard H. Calabrese, Arthur Kavanaugh, John S. Sundy, David Wright, Marsha Wolfson, and Michael A. Becker. “Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.” Arthritis Res Ther 16, no. 2 (March 4, 2014): R60. https://doi.org/10.1186/ar4497.
    Full Text Link to Item
  - Singh, Jasvinder A., William J. Taylor, Nicola Dalbeth, Lee S. Simon, John Sundy, Rebecca Grainger, Rieke Alten, et al. “OMERACT endorsement of measures of outcome for studies of acute gout.” J Rheumatol 41, no. 3 (March 2014): 569–73. https://doi.org/10.3899/jrheum.131246.
    Full Text Link to Item
  - Dalbeth, Nicola, Anthony J. Doyle, Fiona M. McQueen, John Sundy, and Herbert S. B. Baraf. “Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.” Arthritis Care Res (Hoboken) 66, no. 1 (January 2014): 82–85. https://doi.org/10.1002/acr.22059.
    Full Text Link to Item
  - Swigris, Jeffrey J., David L. Streiner, Kevin K. Brown, Amanda Belkin, Kathy E. Green, Frederick S. Wamboldt, and Frederick S. IPFnet Investigators. “Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.” Respir Med 108, no. 1 (January 2014): 181–88. https://doi.org/10.1016/j.rmed.2013.12.009.
    Full Text Link to Item
  - Lionetti, Geraldina, Yukiko Kimura, Laura E. Schanberg, Timothy Beukelman, Carol A. Wallace, Norman T. Ilowite, Jane Winsor, et al. “Using registries to identify adverse events in rheumatic diseases.” Pediatrics 132, no. 5 (November 2013): e1384–94. https://doi.org/10.1542/peds.2013-0755.
    Full Text Link to Item
  - Baraf, Herbert S. B., Michael A. Becker, Sergio R. Gutierrez-Urena, Edward L. Treadwell, Janitzia Vazquez-Mellado, Claudia D. Rehrig, Faith D. Ottery, John S. Sundy, and Robert A. Yood. “Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.” Arthritis Res Ther 15, no. 5 (September 26, 2013): R137. https://doi.org/10.1186/ar4318.
    Full Text Link to Item
  - Becker, Michael A., Herbert S. B. Baraf, Robert A. Yood, Aileen Dillon, Janitzia Vázquez-Mellado, Faith D. Ottery, Dinesh Khanna, and John S. Sundy. “Long-term safety of pegloticase in chronic gout refractory to conventional treatment.” Ann Rheum Dis 72, no. 9 (September 1, 2013): 1469–74. https://doi.org/10.1136/annrheumdis-2012-201795.
    Full Text Link to Item
  - Collard, Harold R., Eric Yow, Luca Richeldi, Kevin J. Anstrom, Craig Glazer, and Craig IPFnet investigators. “Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.” Respir Res 14 (July 13, 2013): 73. https://doi.org/10.1186/1465-9921-14-73.
    Full Text Link to Item
  - Becker, M. A., H. S. B. Baraf, R. A. Yood, A. Dillon, J. Vázquez-Mellado, F. D. Ottery, D. Khanna, and J. S. Sundy. “Long-term safety of pegloticase in chronic gout refractory to conventional treatment.” Annals of the Rheumatic Diseases 72, no. 9 (2013): 1469–74. https://doi.org/10.1136/annrheumdis-2012-201795.
    Full Text
  - Lewis, K., E. L. Bruna, A. Ford, and J. Sundy. “Innovative approach to industrial lighting.” Aistech Iron and Steel Technology Conference Proceedings 1 (2013): 19–26.
  - Wang, Zongyao, John S. Sundy, Catherine M. Foss, Huiman X. Barnhart, Scott M. Palmer, Sallie D. Allgood, Evan Trudeau, Katie M. Alexander, and Marc C. Levesque. “Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity.” J Asthma Allergy 6 (2013): 81–92. https://doi.org/10.2147/JAA.S42695.
    Full Text Open Access Copy Link to Item
  - Sundy, John S. “The rheumatology of gout.” Adv Chronic Kidney Dis 19, no. 6 (November 2012): 404–12. https://doi.org/10.1053/j.ackd.2012.07.012.
    Full Text Link to Item
  - George, R. L., and J. S. Sundy. “Pegloticase for treating refractory chronic gout.” Drugs Today (Barc) 48, no. 7 (July 2012): 441–49. https://doi.org/10.1358/dot.2012.48.7.1813475.
    Full Text Link to Item
  - Yang, Ivana V., John Tomfohr, Jaspal Singh, Catherine M. Foss, Harvey E. Marshall, Loretta G. Que, Erin McElvania-Tekippe, Sarita Florence, John S. Sundy, and David A. Schwartz. “The clinical and environmental determinants of airway transcriptional profiles in allergic asthma.” Am J Respir Crit Care Med 185, no. 6 (March 15, 2012): 620–27. https://doi.org/10.1164/rccm.201108-1503OC.
    Full Text Link to Item
  - Schumacher, H Ralph, John S. Sundy, Robert Terkeltaub, Howard R. Knapp, Scott J. Mellis, Neil Stahl, George D. Yancopoulos, et al. “Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.” Arthritis Rheum 64, no. 3 (March 2012): 876–84. https://doi.org/10.1002/art.33412.
    Full Text Link to Item
  - Neal, K., and J. S. Sundy. “Acute Gout.” Hospital Medicine Clinics 1, no. 1 (January 1, 2012). https://doi.org/10.1016/j.ehmc.2011.11.007.
    Full Text
  - Sundy, J. S., M. A. Becker, and W. B. White. “In reply.” Jama Journal of the American Medical Association 306, no. 18 (November 9, 2011): 1979–80. https://doi.org/10.1001/jama.2011.1617.
    Full Text
  - Que, Loretta G., Jane V. Stiles, John S. Sundy, and W Michael Foster. “Pulmonary function, bronchial reactivity, and epithelial permeability are response phenotypes to ozone and develop differentially in healthy humans.” J Appl Physiol (1985) 111, no. 3 (September 2011): 679–87. https://doi.org/10.1152/japplphysiol.00337.2011.
    Full Text Link to Item
  - Sundy, John S., Herbert S. B. Baraf, Robert A. Yood, N Lawrence Edwards, Sergio R. Gutierrez-Urena, Edward L. Treadwell, Janitzia Vázquez-Mellado, et al. “Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.” Jama 306, no. 7 (August 17, 2011): 711–20. https://doi.org/10.1001/jama.2011.1169.
    Full Text Link to Item
  - Edwards, N. L., J. S. Sundy, A. Forsythe, S. Blume, F. Pan, and M. A. Becker. “Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.” J Med Econ 14, no. 1 (2011): 10–15. https://doi.org/10.3111/13696998.2010.540874.
    Full Text Link to Item
  - Idiopathic Pulmonary Fibrosis Clinical Research Network, Gary W., David A. Zisman, Marvin Schwarz, Kevin J. Anstrom, Harold R. Collard, Kevin R. Flaherty, and Gary W. Hunninghake. “A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.” N Engl J Med 363, no. 7 (August 12, 2010): 620–28. https://doi.org/10.1056/NEJMoa1002110.
    Full Text Link to Item
  - Hershfield, Michael S., L Jackson Roberts, Nancy J. Ganson, Susan J. Kelly, Ines Santisteban, Edna Scarlett, Denise Jaggers, and John S. Sundy. “Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.” Proc Natl Acad Sci U S A 107, no. 32 (August 10, 2010): 14351–56. https://doi.org/10.1073/pnas.1001072107.
    Full Text Link to Item
  - Mandell, Brian F., N Lawrence Edwards, John S. Sundy, Peter A. Simkin, and James C. Pile. “Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.” Cleve Clin J Med 77 Suppl 2 (June 2010): S2-25. https://doi.org/10.3949/ccjm.77.s2.01.
    Full Text Link to Item
  - O’Rourke, K., D. Solomon, J. Sundy, and R. Plenge. “Current Opinion in Rheumatology: Editorial introductions.” Current Opinion in Rheumatology 22, no. 2 (March 1, 2010). https://doi.org/10.1097/BOR.0b013e32833696c0.
    Full Text
  - Sundy, John S. “A natural experiment in the quality of care in gout.” Curr Opin Rheumatol 22, no. 2 (March 2010): 164. https://doi.org/10.1097/BOR.0b013e3283368fca.
    Full Text Link to Item
  - Sundy, John S. “Progress in the pharmacotherapy of gout.” Curr Opin Rheumatol 22, no. 2 (March 2010): 188–93. https://doi.org/10.1097/BOR.0b013e3283369014.
    Full Text Link to Item
  - Shapiro, I., S. C. Stokes, E. J. Wood, and A. S. Kirshner. “Editors’ introduction.” Political Representation, January 1, 2010, 1–12. https://doi.org/10.1017/CBO9780511813146.002.
    Full Text
  - Terkeltaub, R., J. S. Sundy, H. R. Schumacher, F. Murphy, S. Bookbinder, S. Biedermann, R. Wu, S. Mellis, and A. Radin. “The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.” Ann Rheum Dis 68, no. 10 (October 2009): 1613–17. https://doi.org/10.1136/ard.2009.108936.
    Full Text Link to Item
  - Becker, Michael A., H Ralph Schumacher, Katy L. Benjamin, Peter Gorevic, Maria Greenwald, Jeffrey Fessel, Lawrence Edwards, et al. “Quality of life and disability in patients with treatment-failure gout.” J Rheumatol 36, no. 5 (May 2009): 1041–48. https://doi.org/10.3899/jrheum.071229.
    Full Text Link to Item
  - American Lung Association Asthma Clinical Research Centers, Robert A., John G. Mastronarde, Nicholas R. Anthonisen, Mario Castro, Janet T. Holbrook, Frank T. Leone, W Gerald Teague, and Robert A. Wise. “Efficacy of esomeprazole for treatment of poorly controlled asthma.” N Engl J Med 360, no. 15 (April 9, 2009): 1487–99. https://doi.org/10.1056/NEJMoa0806290.
    Full Text Link to Item
  - Kwoh, K., D. Solomon, and J. Sundy. “Editorial introductions.” Current Opinion in Rheumatology 21, no. 2 (March 1, 2009).
  - Sundy, John S. “Gout management: let's get it right this time.” Arthritis Rheum 59, no. 11 (November 15, 2008): 1535–37. https://doi.org/10.1002/art.24201.
    Full Text Link to Item
  - Sundy, John S., Michael A. Becker, Herbert S. B. Baraf, Andre Barkhuizen, Larry W. Moreland, William Huang, Royce W. Waltrip, Allan N. Maroli, Zeb Horowitz, and Zeb Pegloticase Phase 2 Study Investigators. “Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.” Arthritis Rheum 58, no. 9 (September 2008): 2882–91. https://doi.org/10.1002/art.23810.
    Full Text Link to Item
  - Hauswirth, David W., John S. Sundy, Sabrena Mervin-Blake, Carolyn A. Fernandez, Kistie B. Patch, Katie M. Alexander, Sallie Allgood, Patrice D. McNair, and Marc C. Levesque. “Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans.” J Allergy Clin Immunol 122, no. 1 (July 2008): 101–6. https://doi.org/10.1016/j.jaci.2008.03.024.
    Full Text Link to Item
  - White, Julia H., Mathias Chiano, Mark Wigglesworth, Robert Geske, John Riley, Nicola White, Simon Hall, et al. “Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation.” Hum Mol Genet 17, no. 13 (July 1, 2008): 1890–1903. https://doi.org/10.1093/hmg/ddn087.
    Full Text Link to Item
  - Sundy, J. S., D. W. Hauswirth, S. Mervin-Blake, C. A. Fernandez, K. B. Patch, K. M. Alexander, S. Allgood, P. D. Mcnair, and M. C. Levesque. “Smoking is associated with an age-related decline in exhaled nitric oxide (European Respiratory Journal (2007) 30, (1074-1081)).” European Respiratory Journal 31, no. 4 (April 1, 2008): 911. https://doi.org/10.1183/09031936.50087807.
    Full Text
  - Fels, Edward, and John S. Sundy. “Refractory gout: what is it and what to do about it?” Curr Opin Rheumatol 20, no. 2 (March 2008): 198–202. https://doi.org/10.1097/BOR.0b013e3282f4eff5.
    Full Text Link to Item
  - Pillai, S. G., Y. Tang, E. van den Oord, M. Klotsman, K. Barnes, K. Carlsen, J. Gerritsen, et al. “Factor analysis in the Genetics of Asthma International Network family study identifies five major quantitative asthma phenotypes.” Clin Exp Allergy 38, no. 3 (March 2008): 421–29. https://doi.org/10.1111/j.1365-2222.2007.02918.x.
    Full Text Link to Item
  - Levesque, Marc C., David W. Hauswirth, Sabrena Mervin-Blake, Carolyn A. Fernandez, Kistie B. Patch, Katie M. Alexander, Sallie Allgood, Patrice D. McNair, Andrew S. Allen, and John S. Sundy. “Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults.” J Allergy Clin Immunol 121, no. 2 (February 2008): 396-402.e3. https://doi.org/10.1016/j.jaci.2007.09.031.
    Full Text Link to Item
  - Sundy, J. S., D. W. Hauswirth, S. Mervin-Blake, C. A. Fernandez, K. B. Patch, K. M. Alexander, S. Allgood, P. D. McNair, and M. C. Levesque. “Smoking is associated with an age-related decline in exhaled nitric oxide.” Eur Respir J 30, no. 6 (December 2007): 1074–81. https://doi.org/10.1183/09031936.00087807.
    Full Text Link to Item
  - Sundy, John S., and Michael S. Hershfield. “Uricase and other novel agents for the management of patients with treatment-failure gout.” Curr Rheumatol Rep 9, no. 3 (June 2007): 258–64. https://doi.org/10.1007/s11926-007-0041-y.
    Full Text Link to Item
  - Sundy, John S., Nancy J. Ganson, Susan J. Kelly, Edna L. Scarlett, Claudia D. Rehrig, William Huang, and Michael S. Hershfield. “Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.” Arthritis Rheum 56, no. 3 (March 2007): 1021–28. https://doi.org/10.1002/art.22403.
    Full Text Link to Item
  - Webb, Bradley T., Edwin van den Oord, Anthony Akkari, Steve Wilton, Tina Ly, Rachael Duff, Kathleen C. Barnes, et al. “Quantitative linkage genome scan for atopy in a large collection of Caucasian families.” Hum Genet 121, no. 1 (March 2007): 83–92. https://doi.org/10.1007/s00439-006-0285-z.
    Full Text Link to Item
  - Pillai, S. G., M. N. Chiano, N. J. White, M. Speer, K. C. Barnes, K. Carlsen, J. Gerritsen, et al. “Erratum: A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: Evidence for a major susceptibility locus on chromosome 2p (European Journal of Human Genetics (2006) vol. 14 (307-3167) 10.1038/sj.ejhg.5201532).” European Journal of Human Genetics 15, no. 6 (January 1, 2007): 714. https://doi.org/10.1038/sj.ejhg.5201840.
    Full Text
  - Ardoin, Stacy P., and John S. Sundy. “Update on nonsteriodal anti-inflammatory drugs.” Curr Opin Rheumatol 18, no. 3 (May 2006): 221–26. https://doi.org/10.1097/01.bor.0000218940.04613.cc.
    Full Text Link to Item
  - Pillai, Sreekumar G., Mathias N. Chiano, Nicola J. White, Marcy Speer, Kathleen C. Barnes, Karin Carlsen, Jorrit Gerritsen, et al. “A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p.” Eur J Hum Genet 14, no. 3 (March 2006): 307–16. https://doi.org/10.1038/sj.ejhg.5201532.
    Full Text Link to Item
  - Ganson, Nancy J., Susan J. Kelly, Edna Scarlett, John S. Sundy, and Michael S. Hershfield. “Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.” Arthritis Res Ther 8, no. 1 (2006): R12. https://doi.org/10.1186/ar1861.
    Full Text Link to Item
  - Sundy, John S., William A. Wood, Janet L. Watt, Joel N. Kline, and David A. Schwartz. “Safety of incremental inhaled lipopolysaccharide challenge in humans.” J Endotoxin Res 12, no. 2 (2006): 113–19. https://doi.org/10.1177/09680519060120020701.
    Full Text Link to Item
  - Ganson, N. J., S. J. Kelly, E. Scarlett, J. S. Sundy, and M. S. Hershfield. “Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.” Arthritis Research and Therapy 8, no. 1 (December 2, 2005). https://doi.org/10.1186/ar1861.
    Full Text
  - Savage, C., E. W. St. Clair, and J. S. Sundy. “Emerging treatments for rheumatoid arthritis: Update.” Consultant 45, no. 9 (August 1, 2005): 984–95.
  - Schiffman, Susan S., Clare E. Studwell, Lawrence R. Landerman, Katherine Berman, and John S. Sundy. “Symptomatic effects of exposure to diluted air sampled from a swine confinement atmosphere on healthy human subjects.” Environ Health Perspect 113, no. 5 (May 2005): 567–76. https://doi.org/10.1289/ehp.6814.
    Full Text Link to Item
  - Hauswirth, David W., and John S. Sundy. “Bioaerosols and innate immune responses in airway diseases.” Curr Opin Allergy Clin Immunol 4, no. 5 (October 2004): 361–66. https://doi.org/10.1097/00130832-200410000-00006.
    Full Text Link to Item
  - Pillai, Sreekumar G., Diane J. Cousens, Ashley A. Barnes, Peter T. Buckley, Mathias N. Chiano, Louise K. Hosking, Lee-Ann Cameron, et al. “A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma.” Pharmacogenetics 14, no. 9 (September 2004): 627–33. https://doi.org/10.1097/00008571-200409000-00007.
    Full Text Link to Item
  - Law, Amy W., Shelby D. Reed, John S. Sundy, and Kevin A. Schulman. “Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey.” J Allergy Clin Immunol 111, no. 2 (February 2003): 296–300. https://doi.org/10.1067/mai.2003.68.
    Full Text Link to Item
  - McCrory, D. C., J. W. Williams, R. J. Dolor, R. N. Gray, J. T. Kolimaga, S. Reed, J. Sundy, and D. L. Witsell. “Management of allergic rhinitis in the working-age population.” Evid Rep Technol Assess (Summ), no. 67 (January 2003): 1–4.
    Link to Item
  - Sundy, J. S. “COX-2 inhibitors in rheumatoid arthritis.” Curr Rheumatol Rep 3, no. 1 (February 2001): 86–91. https://doi.org/10.1007/s11926-001-0055-9.
    Full Text Link to Item
  - Sundy, J. S., and B. F. Haynes. “Cytokines and adhesion molecules in the pathogenesis of vasculitis.” Curr Rheumatol Rep 2, no. 5 (October 2000): 402–10. https://doi.org/10.1007/s11926-000-0040-8.
    Full Text Link to Item
  - Sempowski, G. D., L. P. Hale, J. S. Sundy, J. M. Massey, R. A. Koup, D. C. Douek, D. D. Patel, and B. F. Haynes. “Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy.” J Immunol 164, no. 4 (February 15, 2000): 2180–87. https://doi.org/10.4049/jimmunol.164.4.2180.
    Full Text Link to Item
  - Lee, D. M., H. F. Staats, J. S. Sundy, D. D. Patel, G. D. Sempowski, R. M. Scearce, D. M. Jones, and B. F. Haynes. “Immunologic characterization of CD7-deficient mice.” J Immunol 160, no. 12 (June 15, 1998): 5749–56.
    Link to Item
  - Kremer, J. M., G. S. Alarcón, M. E. Weinblatt, M. V. Kaymakcian, M. Macaluso, G. W. Cannon, W. R. Palmer, et al. “Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.” Arthritis Rheum 40, no. 10 (October 1997): 1829–37. https://doi.org/10.1002/art.1780401016.
    Full Text Link to Item
  - Alarcón, G. S., J. M. Kremer, M. Macaluso, M. E. Weinblatt, G. W. Cannon, W. R. Palmer, E. W. St Clair, et al. “Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.” Ann Intern Med 127, no. 5 (September 1, 1997): 356–64. https://doi.org/10.7326/0003-4819-127-5-199709010-00003.
    Full Text Link to Item
  - Lee, D. M., J. S. Sundy, H. F. Staats, D. D. Patel, and B. F. Haynes. “Initial characterization of cd7 deficient mice: evidence of a role for CD7 in regulation of thymocyte development.” Journal of Investigative Medicine 44, no. 3 (January 1, 1996).
  - Sundy, J. S., N. B. Allen, and D. J. Sexton. “Rocky Mountain spotted fever presenting with acute monarticular arthritis.” Arthritis Rheum 39, no. 1 (January 1996): 175–76. https://doi.org/10.1002/art.1780390126.
    Full Text Link to Item
  - Sundy, J. S., and B. F. Haynes. “Pathogenic mechanisms of vessel damage in vasculitis syndromes.” Rheum Dis Clin North Am 21, no. 4 (November 1995): 861–81.
    Link to Item
  - Russo, D. M., J. S. Sundy, J. F. Young, H. C. Maguire, and W. P. Weidanz. “Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum.” J Immunol 143, no. 2 (July 15, 1989): 655–59.
    Link to Item
  - Russo, D. M., J. S. Sundy, H. C. Maguire, and W. P. Weidanz. “Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators.” Adv Exp Med Biol 251 (1989): 203–7. https://doi.org/10.1007/978-1-4757-2046-4_19.
    Full Text Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Global Scholarship

Research

Selected Grants

Selected Publications

Academic Articles